Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics
详细信息 查看全文
- 作者：Mustapha Haddach ; Michael K. Schwaebe ; Jerome Michaux ; Johnny Nagasawa ; Sean E. O'Brien ; Jeffrey P. Whitten ; Fabrice Pierre ; Pauline Kerdoncuff ; Levan Darjania ; Ryan Stansfield ; Denis Drygin ; Kenna Anderes ; Chris Proffitt ; Josh Bliesath ; Adam Siddiqui-Jain ; May Omori ; Nanni Huser ; William G. Rice ; David M. Ryckman
- 刊名：ACS Medicinal Chemistry Letters
- 出版年：2012
- 出版时间：July 12, 2012
- 年：2012
- 卷：3
- 期：7
- 页码：602-606
- 全文大小：237K
- 年卷期：v.3,no.7(July 12, 2012)
- ISSN：1948-5875
文摘
Accelerated proliferation of solid tumor and hematologic cancer cells is linked to accelerated transcription of rDNA by the RNA polymerase I (Pol I) enzyme to produce elevated levels of rRNA (rRNA). Indeed, upregulation of Pol I, frequently caused by mutational alterations among tumor suppressors and oncogenes, is required for maintenance of the cancer phenotype and forms the basis for seeking selective inhibitors of Pol I as anticancer therapeutics. 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (CX-5461, 7c) has been identified as the first potent, selective, and orally bioavailable inhibitor of RNA Pol I transcription with in vivo activity in tumor growth efficacy models. The preclinical data support the development of CX-5461 as an anticancer drug with potential for activity in several types of cancer.